ClinicalTrials.gg
Not yet recruitingNCT06894160Updated Jun 4, 2025

Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases

An interventional study of Adults EXPLORER in Neuromuscular Disorders, sponsored by MarsiBionics. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Neuromuscular Diseases with a site in Spain — 5 open to participants now, 10 under way, 3 of them phase 3. Neuromuscular Diseases · Spain.

Planned enrollment
28th of 30
7 · median 55
Started
2025
with 5 others
No phase
14 of 35
2 open now
Registered
29th of 35
by date
Lead sponsor
6 of 35
MarsiBionics

Among the 35 studies in Neuromuscular Diseases with a site in Spain, this one is the 28th largest by planned enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 with no phase, and was the 29th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

5 of the 35 studies in Neuromuscular Diseases with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Neuromuscular Diseases with a site in Spain, or all of them as a file.
02

Study summary

Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities.The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.

Read the detailed description

Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities. The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.

This study will involve testing the gait-assistance exoskeleton in healthy patients during the first phase, and in patients with stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), and muscular dystrophy (LM) during the second phase. The study will consist of two phases:

Phase 1: One visit with the device in healthy patients to assess the initial safety and comfort of the device.

Phase 2: A screening visit (S0) followed by two treatment visits with the device (V1-V2) in patients with ACV, DCA, EM, and LM to determine the effectiveness of the device in treating motor impairments caused by these conditions.

The goal of the study is to evaluate the safety and usability of the device in patients with ACV, DCA, EM, and LM, in order to identify potential benefits in improving gait, muscle strength, and overall functionality in this patient group.

03

Conditions studied

  • Neuromuscular Disorders

Keywords

  • gait
  • robotics
  • neuromuscular disorders
  • rehabilitation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria related to the device characteristics:

  • Weight \< 100 kg.
  • Hip width between 30 - 45 cm.
  • Distance from the hip joint center to the knee joint center: 36 cm - 50 cm.
  • Distance from the knee joint center to the floor: 43.5 cm - 59.5 cm.
  • Patients must be able to follow simple instructions.
  • MAS \< 3 in lower limbs.
  • EU shoe size between 36 and 45.
  • Absence of pathology affecting movement (only valid for phase 1 of the current study).

Inclusion criteria

Inclusion criteria related to the study:

  • Age 18-85 years.
  • Diagnosis of stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), muscular dystrophy (LM), or cerebral palsy (PC).
  • Gait difficulty: those who require assistance to walk using technical aids, assistance, or supervision from others.
  • FAC score in participants with DCA, stroke, or MS \< 4.
  • WISCI II score in participants with MD \< 20.

Exclusion criteria

Exclusion Criteria:

  • Spasticity (MAS) = 3 in lower limbs.
  • Skin alterations in the areas of contact with the device.
  • Planned surgical intervention during the study duration.
  • Two or more osteoporotic fractures in the lower limbs in the last 2 years.
  • Presence of other conditions that cause exercise intolerance (such as uncontrolled hypertension, coronary artery diseases, arrhythmia, congestive heart failure, severe lung disease).
  • Surgical operation in the 3 months prior to the start of the study on the limbs and/or spine.
  • Psychiatric disorders that interfere with proper use of the device or participation in the study, such as impulsivity or inability to understand simple instructions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    Adults EXPLORER

    Two sessions with the robotic gait device in patients with neuromuscular diseases.

    Device: Adults EXPLORER

Interventions

  • DeviceAdults EXPLORER

    Two sessions with the robotic gait device in patients with neuromuscular diseases.

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    Occurrence of any serious adverse event to the participant or the caregiver

    Time frame: Through study completion, an average of 1 month

  2. Falls prevalence

    Number of falling events occurred from the participant or caregiver

    Time frame: Through study completion, an average of 1 month

  3. Heart Rate

    Beats per minute

    Time frame: Through study completion, an average of 1 month

  4. Skin integrity

    Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

    Time frame: Through study completion, an average of 1 month

  5. Device usage time

    Time using the device

    Time frame: Through study completion, an average of 1 month

  6. Level of Spasticity

    Evaluation of spasticity with Modified Ahsworth Scale

    Time frame: Through study completion, an average of 1 month

  7. Level of fatigue

    Fatigue of both the participant and the therapist, Measured with the Borg scale

    Time frame: Through study completion, an average of 1 month

  8. Donning and doffing time

    Time to don and doff the device to each participant

    Time frame: Through study completion, an average of 1 month

  9. Level of assistance a participant requires for walking

    Measure with FAC scale

    Time frame: Through study completion, an average of 1 month

  10. Walking ability of individuals with spinal cord injuries

    Measure with WISCII (SCI) scale

    Time frame: Through study completion, an average of 1 month

  11. TUG

    The Time Up and Go test is used to assess a participant's mobility and balance

    Time frame: Through study completion, an average of 1 month

  12. 10MWT

    The 10-Meter Walk Test is used to assess walking speed by measuring the time taken to walk 10 meters at a comfortable pace.

    Time frame: Through study completion, an average of 1 month

  13. QUEST 2.0

    Using the Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale

    Time frame: at the end of the intervention, an average of 1 month

  14. Blood Pressure

    Measure in mmHg

    Time frame: Through study completion, an average of 1 month

  15. Oxygen Saturation

    It analyzes this absorption and calculates the SpO₂

    Time frame: Through study completion, an average of 1 month

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2025, 0 months later.

Of 84 interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 25, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Jul 15, 2025
CompletionEst.
Aug 1, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06894160
Lead sponsor
MarsiBionics
Collaborators
Hospital Universitario La Paz
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Jul 15, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jun 4, 2025

Study contacts

Carlos Cumplido Trasmonte
Contact
carlos.cumplido@marsibionics.com
+34918711900

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion